EP2772249A1 — Method and composition for treating ocular hypertension and glaucoma
Assigned to Santen Pharmaceutical Co Ltd · Expires 2014-09-03 · 12y expired
What this patent protects
The present invention relates to an ophthalmic aqueous solution for treating ocular hypertension and glaucoma, comprising PGF2α analogue as an active ingredient, wherein said ophthalmic aqueous solution contains nonionic surfactant, stabilizing agent and substantially no preserva…
USPTO Abstract
The present invention relates to an ophthalmic aqueous solution for treating ocular hypertension and glaucoma, comprising PGF2α analogue as an active ingredient, wherein said ophthalmic aqueous solution contains nonionic surfactant, stabilizing agent and substantially no preservatives in a container consisting essentially of polyethylene; and the polyethylene is low density polyethylene (LDPE).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.